Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $50 from $52 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences Files New Shelf Registration Statement
- Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)
- Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA
- Ideaya Biosciences price target raised to $58 from $52 at Wedbush
- Ideaya Biosciences price target raised to $54 from $50 at Guggenheim